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Case Presentation
A 78-year-old male ex-smoker (49 
pack-years) presented with an abnor-
mal shadow in the left lung, as observed 
via chest radiography, and computed 
tomography revealed a 6 cm solitary 
tumor with aorta invasion in the left 
lower lung (Fig. 1A, B). Biopsy of 
the lung tumor revealed a malignant 
neoplasm that was organized into 
moderate culture type squamous cell 
carcinoma (SCC) with cornification 
(Fig. 2A), and tumor cells with solid 
growth had invaded the airway wall. 
Immunohistochemistry (IHC) analysis 
revealed diffuse and strongly positive 
signals for pan-cytokeratin, cytokeratin 
5/6, and p40 (Fig. 2B), although the cells 
were negative for thyroid transcription 
factor-1, and CD56. Furthermore, the 
tumor cells were diffusely and strongly 
positive for anaplastic lymphoma 
kinase (ALK; D5F3 rabbit monoclonal 
antibody; Cell Signalling Technology; 
Fig. 2C). Fluorescence in situ hybrid-
ization (FISH), with break apart probes 
for the ALK gene, revealed the pres-
ence of EML4-ALK rearrangement 
(Fig. 2D), and the tumor cells were 
confirmed to be diffusely and strongly 
positive (3+) for ALK via intercalated 
antibody-enhanced IHC (Fig. 2E). We 
treated the patient with alectinib, as it is 
more selective than crizotinib for inhib-
iting ALK tyrosine kinase. However, 
6 weeks later, computed tomogra-
phy revealed that the tumor had not 
responded (Fig. 1C), although we con-
tinued treatment without any remark-
able toxicities.
DISCUSSION
The present case is the first report of 
SCC harboring an EML4-ALK rear-
rangement that did not exhibit a durable 
response to alectinib. In a subset of 
non–small-cell lung carcinoma, rear-
rangement of the EML4 and ALK genes 
creates EML4-ALK, which is an onco-
genic fusion gene that encodes a chi-
meric protein with constitutive kinase 
activity that is most commonly seen 
in adenocarcinoma.1 Wong et al.1 have 
reported that none of their 34 SCC cases 
exhibited EML4-ALK rearrangement, 
whereas Yoshida et al.2 have reported 
that ALK-positive cancers commonly 
coexpress thyroid transcription fac-
tor-1 and p63. Therefore, it is difficult 
to use p63 immunostaining to confirm 
SCC. However, Bishop et al.3 have 
reported that p40 has similar sensitivity 
and greater specificity for SCC, com-
pared with p63. Therefore, the authors 
suggested that p40 might be appropri-
ate for routine use in diagnosing pul-
monary SCC. Similarly, in this case, 
we used cornification and p40 immu-
nostaining to confirm our diagnosis of 
lung SCC. Furthermore, we used FISH 
and the intercalated antibody enhanced 
polymer method of IHC to confirm that 
the tumor was strongly ALK positive 
(3+). Similarly, a previous report has 
described how screening for ALK rear-
rangement via IHC, followed by confir-
matory FISH, is a rational diagnostic 
algorithm.4 Therefore, we believe that 
this diagnostic algorithm is appropriate 
for diagnosing SCC that harbors ALK 
rearrangement.
Alectinib is known to be highly 
effective and safe in patients with the 
ALK rearrangement.5 Furthermore, 
compared with crizotinib, alectinib is a 
more selective ALK inhibitor and may 
have a higher efficacy in ALK-positive 
lung cancer. However, given that we did 
not observe any response to alectinib in 
the present case, it is possible SCC har-
boring ALK rearrangement may be less 
responsive to ALK inhibitors.
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FIGURE 1.  Imaging findings. A, 
Chest radiography at admission 
revealed a mass in the left lower field. 
B, Chest CT at admission revealed a 
lung mass with aorta invasion in the 
left lower lobe. C, Chest CT revealed 
a moderate response in the left lower 
lung after 6 weeks of treatment with 
alectinib. CT, computed tomography.
FIGURE 2.  Pathology findings. A, 
Low-power image of a hematoxy-
lin and eosin-stained section from 
the lung tumor reveals a malignant 
neoplasm that was organized into 
moderate culture type squamous 
cell carcinoma with cornification. 
B, Immunohistochemical analysis 
reveals that the tumor cells were dif-
fusely and strongly positive for p40. 
C, Immunohistochemical analysis 
revealed strong diffuse ALK positiv-
ity. D, Fluorescence in situ hybrid-
ization analysis of the ALK locus, 
using a break-apart probe strategy, 
reveals ALK rearrangement in 20% 
of the tumor cells, as indicated by 
the split red/green signals (arrows). 
E, Immunohistochemical analysis of 
the lung tumor with the intercalated 
antibody-enhanced polymer method 
reveals diffuse and strong ALK posi-
tivity (3+). ALK, anaplastic lymphoma 
kinase.
